Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor

Overview of attention for article published in Molecular Cancer Therapeutics, July 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 32 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 13 X posts from 10 X users, with an upper bound of 19,832 followers.

RT @LurieCancer: Research from Lurie Cancer Center member @vanderweelemd in @MCT_AACR examines resistance mechanisms to AR-targeted therapy…

18 Jul 2022

Reply Repost Favourite

Research from Lurie Cancer Center member @vanderweelemd in @MCT_AACR examines resistance mechanisms to AR-targeted therapy for #prostatecancer https://t.co/pY2s66hVHB #pcsm

18 Jul 2022

Reply Repost Favourite

RT @vanderweelemd: Excited to share our latest work, led by @R_AdelaiyeOgala looking at resistance mechanisms in advanced pca: Targeting…

17 Aug 2020

Reply Repost Favourite

Inhibition of the PI3K/AKT pathway can block glucocorticoid receptor (GR) activity and overcome GR-mediated resistance to Androgen Receptor-targeted therapy in #ProstateCancer, Adelaiye-Ogala et al report here: https://t.co/ZyApqEsHLq @theNCI https://t.co

15 Jul 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 9 additional X posts.